Vol. 3 No. 12 (2023)
Reimbursement Reviews

Dupilumab (Dupixent)

Published December 12, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dupilumab (Dupixent), 200 mg single-use syringe (200 mg per 1.14 mL) and 300 mg single-use syringe (300 mg per 2 mL), subcutaneous injection.
  • Indication: For the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.